EP0179559A2 — Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
Assigned to Warner Lambert Co LLC · Expires 1986-04-30 · 40y expired
What this patent protects
6-[2-lSubstituted-pyrrol-1-yl)alkyl]pyran-2-ones of formula I and the corresponding ring-opened hydroxy-acids derived therefrom are potent inhibitors of the enzyme 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMG-CoA reductase), and are thus useful hypolipidemic and hypoc…
USPTO Abstract
6-[2-lSubstituted-pyrrol-1-yl)alkyl]pyran-2-ones of formula I and the corresponding ring-opened hydroxy-acids derived therefrom are potent inhibitors of the enzyme 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMG-CoA reductase), and are thus useful hypolipidemic and hypocholesterolemic agents. Pharmaceutical compositions containing such compounds. and a method of preparing the compounds are also disclosed.
Drugs covered by this patent
- Zetia (EZETIMIBE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.